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Joanne N Davis1, Clinton Medbery III2, Sanjeev Sharma3, Adnan Danish4 and Anand Mahadevan5*Abstract
Background: The RSSearch™ Registry is a multi-institutional, observational, ongoing registry established to
standardize data collection from patients treated with stereotactic radiosurgery (SRS) and/or stereotactic body
radiotherapy (SBRT). This report describes the design, patient demographics, lesion characteristics, and SRS/SBRT
treatment patterns in RSSearch™. Illustrative patient-related outcomes are also presented for two common
treatment sites – brain metastases and liver metastases.
Materials and methods: Thirty-nine US centers participated in RSSearch™. Patients screened for SRS/SBRT were
eligible to be enrolled. Descriptive analyses were performed to assess patient characteristics, physician treatment
practices, and clinical outcomes. Kaplan-Meier analysis was used to determine overall survival (OS), local
progression-free (LPFS), and distant disease-free survival (DDFS).
Results: From January, 2008 – January, 2013, 11,457 patients were enrolled. The median age was 67 years (range
7–100 years); 51% male and 49% female. Forty-six percent had no prior treatment, 22% had received chemotherapy,
19% radiation therapy and 17% surgery. There were 11,820 lesions from 65 treatment locations; 54% extracranial
and 46% intracranial. The most common treatment locations were brain/cranial nerve/spinal cord, lung, prostate
and liver. Metastatic lesions accounted for the majority of cases (41.6%), followed by primary malignant (32.9%),
benign (10.9%), recurrent (9.4%), and functional diseases (4.3%). SRS/SBRT was used with a curative intent in 39.8%
and palliative care in 44.8% of cases. The median dose for all lesions was 30 Gy (range < 1 – 96.7 Gy) delivered in a
median number of 3 fractions. The median dose for lesions in the brain/cranial nerve/spinal cord, lung, liver,
pancreas and prostate was 24, 54, 45, 29 and 36.25 Gy, respectively. In a subset analysis of 799 patients with 952
brain metastases, median OS was 8 months. For patients with a Karnofsky performance score (KPS) > 70, OS was
11 months vs. 4 months for KPS ≤ 70. Six-month and 12-month local control was 79% and 61%, respectively for
patients with KPS ≤ 70, and 85% and 74%, respectively for patients with KPS > 70. In a second subset analysis
including 174 patients with 204 liver metastases, median OS was 22 months. At 1-year, LPFS and DDFS rates were
74% and 53%, respectively. LPFS.
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Conclusion: This study demonstrates that collective patterns of care and outcomes research for SRS/SBRT can be
performed and reported from data entered by users in a common database. The RSSearch™ dataset represents
SRS/SBRT practices in a real world setting, providing a useful resource for expanding knowledge of SRS/SBRT
treatment patterns and outcomes and generating robust hypotheses for randomzed clinical studies.
Keywords: Stereotactic radiosurgery, Stereotactic body radiation therapy, Registry, Brain metastases, Lung cancer,
Liver metastases, Prostate cancer, Pancreatic cancerIntroduction
Stereotactic radiosurgery (SRS) has been used to treat intra-
cranial and spinal benign and malignant lesions, as well as
functional disorders of the brain for several decades [1-4].
Lars Leksell first described SRS as a technique for the non-
invasive destruction of intracranial tissue or lesions where
surgery was not considered an option and designed and
built the first Gamma Unit for clinical use in the 1950’s
[5,6]. Between 1968–1982, the Stockholm group treated
762 patients with intracranial lesions including meningi-
omas, pituitary tumors, pineal gland tumors, acoustic tu-
mors, arterio-venous malformations (AVM), and functional
diseases including trigeminal neuralgia, anxiety and com-
pulsive disorders [6]. The technology continued to evolve
with the development of linear accelerator-based radiosur-
gery [7], frameless radiosurgery, three dimensional comput-
erized treatment planning systems and image guidance,
which led to wide-spread use of SRS for the treatment of
intracranial lesions. SRS is now used as an alternative to
surgical resection for poorly accessible intracranial lesions
and in eloquent areas, primary therapy for benign and re-
current tumors and adjuvant treatment for post-surgical
residual lesions. The SRS dose typically ranges from
12–24 Gy for benign and malignant lesions and is
dependent on lesion location, size and distance to critical
normal structures. Recent studies have shown SRS can
achieve similar local control rates to surgical resection for
meningiomas and > 90% 5-year local control rates for
pituitary adenomas, acoustic neuromas [8-10].
In the early 1990’s, the concept of stereotactic body
radiotherapy (SBRT), delivering a high dose of radiation to
an extracranial target within the body in either a single or
a few fractions was developed from the techniques and
procedures of SRS [11]. Initial studies further developed
the techniques to deliver SBRT to lung and liver lesions
[12-14]. SBRT is characterized by patient immobilization,
target localization and tracking software, limiting high
doses of radiation to normal tissues, accounting for organ
motion and sub-millimeter accuracy. Improvements in all
these areas with rapid advances in SRS/SBRT technology
have resulted in expansion of SBRT clinical applica-
tions and an exponential increase in patients treated.
In the past decade, SBRT has been used as a treatment for
lesions of the prostate [15-19], pancreas [20-23], head andneck [24-26], kidney [27], breast [28], and gynecological
tumors [29-31].
Despite increased knowledge of the technology and clin-
ical outcomes reported from single institutions, informa-
tion on physician practice patterns of SRS and SBRT in
the daily clinical practice is limited. A registry provides a
systematic and inclusive database of information which
can reveal and evaluate the effectiveness of management
practices in the real world [32]. In contrast to a clinical
trial, where patient enrollment is defined by specific inclu-
sion and exclusion criteria, treatment is dictated by proto-
col guidelines, and treatment evaluation is measured at
specific follow-up time intervals, a registry documents ac-
tual care, representing a broad spectrum of patients where
treatments are not specified by protocol guidelines and
patient follow-up schedules are conducted in a real-life
setting. A registry can provide information as to whether
clinicians are adhering to practice guidelines, may comple-
ment randomized clinical trials and/or identify new clin-
ical applications and treatment benefits [33-35]. Such
patterns of care, utilization and outcomes can help design
and conduct future trials more effectively.
The RSSearch™ Registry is an ongoing, observational,
multi-institutional registry collecting patient and tumor
characteristics, treatment plan and treatment delivery in-
formation, toxicity, and outcome data from patients
treated with SRS/SBRT. This report describes the design
and methods of the registry, the baseline demographics
and clinical characteristics of the enrolled patients and
SRS/SBRT treatment management patterns. It also illus-
trates the feasibility of generating useful outcomes data
outside the confines of tightly controlled clinical trials.
Materials and methods
The RSSearch™ Registry was conceptualized and designed
by a board of RSSearch™ Clinical Advisors in 2006. The
RSSearch™ Clinical Advisory Committee is comprised of
radiation oncologists, neurosurgeons, surgeons, medical
oncologists, and medical physicists to create and oversee
the scientific conduct of the registry. The goals and objec-
tives are to provide a method to collect standardized data
on the use of SRS/SBRT treatment practices and out-
comes to help determine the most effective clinical
use of SRS/SBRT in management of patients with life
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RSSearch™ includes patient demographics, tumor/lesion
characteristics, treatment locations, treatment plan and
treatment delivery information, toxicity, and clinical
outcomes, including symptom control, lesion response,
patient survival, and disease progression.
Through an initial grant provided by Accuray Incorpo-
rated (Sunnyvale, CA), a third-party medical software and
web management company, Advertek Inc. (Louisville, KY),
was contracted to provide services to design, store, and
maintain the web-based database. The RSSearch™ Registry
is currently managed by the Radiosurgery Society®, a multi-
disciplinary non-profit organization aimed at advancing
the science and clinical practice of radiosurgery [36]. Add-
itional clinical oversight is provided by the RSSearch™
Clinical Advisory Committee. The database meets all re-
quirements to comply with the Health Insurance Portabil-
ity and Accountability Act to maintain system security,
transmission of data and patient confidentiality. Select pa-
tient identifying information is recorded in RSSearch™ as
needed for registry operations, but is visible to the partici-
pating site only and further protected by robust security
systems put in place by Advertek. A role-based security
model is implemented to restrict access to only the appro-
priate information based on the user’s role in the registry.
Quality assurance measures have been built into the sys-
tem to reduce error and redundancy. These include explicit
definitions for each question and set of variables to help
reduce interpretive error and improve quality control. Elec-
tronic data ranges, logic checks and data entry require-
ments are implemented within the system to reduce entry
of incorrect or duplicate data. All participants are trained
on the system.
All centers treating patients with SRS/SBRT clinically
are offered and encouraged to participate. Participation
is voluntary and no compensation is provided either to
patients or participating centers. Each principal investiga-
tor is provided a copy of the RSSearch™ Registry protocol,
case report forms, sample patient informed consent, and
web-based training for data entry and database navigation.
Institutional Review Board (IRB) approval is required at
all participating centers. All patients who are screened for
potential SRS/SBRT treatment are eligible to be included
in the RSSearch™ Registry. All prospective patients are re-
quired to sign an informed consent, as required by indi-
vidual IRBs, prior to the patient’s data entered into the
RSSearch™ Registry. Retrospective analysis of RSSearch™ is
conducted from prospectively entered data. Data is en-
tered into RSSearch™ voluntarily per institutional guide-
lines. Individual sites have access to their own individual
dataset. The RSSearch™ administrator has access to de-
identified aggregate data for quality assurance purposes
and data are reviewed periodically for data completeness.
Requests for de-identified aggregate data can be submittedby RSSearch™ participants to the RSS and requests are
reviewed by the RSSearch™ Review Committee.
Patient demographics are captured during the screen-
ing process and include gender, ethnicity, age, weight,
height, smoking history and Karnofsky performance score.
Information on referral sources, primary and secondary
payer information, previous treatments, and co-morbidities
are also captured during the screening process. SRS/SBRT
treatment sites are classified using the World Health
Organization (WHO) International Classification of
Diseases (ICD), version 9 codes. Tumor characteristics
including TNM stage, histology/cytology, lesion size,
tumor markers and data from diagnostic imaging are
recorded. All patients were treated with the CyberKnife™
Robotic Radiosurgery System, Accuray Inc., Sunnyvale, CA.
Both manual and automatic treatment planning upload
capabilities are available in RSSearch™ to capture treatment
planning and delivery information. Treatment planning
data fields include treatment planning system version,
method of dose calculation, dose optimization method,
number of fractions, number of fiducials, path set, tracking
method, number of monitor units, prescription dose,
maximum dose, number of nodes, collimator type and size,
doses to organs at risk, treatment times, set-up times, and
delivery times and are captured for each treated lesion.
RSSearch™ has an extensive outcome and follow-up data
section that captures toxicity, lesion response, disease-
progression, tumor markers, surrogate endpoints, survival,
information from post-treatment imaging, and additional
treatments. Toxicity reporting utilizes the Common Tox-
icity Criteria for Adverse Event Reporting, version 3. Pa-
tient demographics, lesion characteristics, and treatment
management practices were examined using descriptive
statistics using GraphPad and Instat Software, La Jolla,
CA. Overall survival was calculated from the date the pa-
tient was evaluated for SBRT. Local failure and distant
failure patterns were determined from the date of SBRT
evaluation to the first date of physician reported-failure.
Distant disease included disease outside of the local treat-
ment area. Survival curves were plotted based on the
Kaplan-Meier method.
Results
Patient characteristics
Between January 2008 and January 2013, 11,457 patients
from 39 participating centers in the US were enrolled in
the RSSearch™ Registry. Ninety-two percent of the sub-
jects were enrolled prospectively and 7.8% of the subjects
had their data retrospectively entered into the database.
The median age of the patients at time of enrollment was
67 years (range 7–100); with 89% of patients age 50 years
and older (Table 1). Fifty-one percent of the patients were
male and 49% were female. Eighty-nine percent of the
patients were Caucasian, 6.6% African-American, 1.8%
Table 1 Patient characteristics and demographics
Variable (N) N (%)
Patients enrolled 11457
Gender (11345)
Male 5836 (51%)
Female 5509 (49%)
Median age (range), years 67 (7 – 100)
Age groups (10886)
< 20 21 (0.2%)
20 – 29 115 (1.1%)
30 – 39 235 (2.2%)
40 – 49 829 (7.6%)
50 – 59 1879 (17.3%)
60 – 69 3083 (28.3%)
70 – 79 3183 (29.2%)
≥ 80 1541 (14.2%)
Median weight (pounds) 170
Median height (inches) 67
Median Karnofsky score (range) 90 (10–100)
Race/ethnicity (10352)
Caucasian 9269 (89.5%)
Black/African American 682 (6.6%)
Hispanic 185 (1.8%)
Asian 83 (0.8%)
Pacific-Asian Islander 13 (0.1%)
Other 51 (0.5%)
Don’t know 69 (0.7%)
Primary health insurance (10547)
Private 40%
Medicare 54.4%
Self-pay/none 0.7%
Patients not treated with SRS/SBRT 1060 (9%)
Reason for not completing SRS/SBRT (1060)
SRS/SBRT determined not clinically
appropriate after further review
272 (25.7%)
Patient has extensive disease 226 (21.3%)
Patient declined SRS/SBRT 148 (14.0%)
Watchful waiting indicated 109 (10.3%)
Payment not pre-authorized 53 (5.0%)
Alternative insurance-covered
treatment elected
44 (4.2%)
Other 29 (2.7%)
Patient not able to tolerate SRS/SBRT 16 (1.5%)
Co-morbidities rule out SRS/SBRT 15 (1.4%)
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excellent baseline performance status with a median Kar-
nofsky score of 90% (10–100).
The majority of patients were referred to SRS/SBRT
treatment centers from medical oncologists (30%), neu-
rosurgeons (17%), radiation oncologists (11%), urologists
(8%), and cardio-thoracic surgeons (5%). Other referral
specialties included pulmonology (4%), primary care (2%),
neurology (1%), general surgery (1%), and gynecology
(0.5%). Four percent of the patients were self-referred.
Medicare was listed as the primary health insurance payer
for 54.4% of the patients, private insurance for 40.8% of
the patients, and 0.7% of the patients were uninsured or
paid out-of-pocket (Table 1). At the time of the analysis,
1060 (9%) of the screened patients did not undergo
SRS/SBRT treatment. Reasons for not completing SRS/SBRT
treatment included those deemed inappropriate after further
review (272 patients; 25.7% of non-treated patients),
extensive disease (226 patients; 21.3% of non-treated
patients), or patient decision not to pursue treatmentTable 2 Clinical characteristics of the patients enrolled at
baseline
Variable (N) N (%)
Number of screened entries 11820
Prior Treatment(s)
None 5399 (45.7%)
Chemotherapy 2597 (22.0%)
External beam radiation 2262 (19.1%)
IMRT 239 (2%)
CyberKnife Robotic Radiosurgery 419 (3.5%)
Other radiosurgery 120 (1.0%)
Proton therapy 7 (0.1%)
Brachytherapy 34 (0.3%)
Surgery 2096 (17.7%)
Hormone therapy 179 (1.5%)
Cryotherapy 11 (0.1%)
Immunotherapy 7 (0.1%)
Other treatment 443 (3.8%)
Surgically inoperable 1728 (14.6%)
Medically inoperable 1188 (10.1%)
Co-morbidities listed for medically inoperable
patients (N = 1188)*
Age 24 (2%)
Cardiac 206 (17.3%)
Neurological 22 (1.9%)
Pulmonary 771 (64.9%)
Vascular 41 (3.45%)
* Co-morbid conditions are not mutually exclusive.
Table 3 Lesion characteristics and most common lesion
location and histology
Variable (N) N (%)
All lesions – lesion type (11154)
Arterio-venous malformation 92 (0.8%)
Benign tumor 1218 (10.9%)
Malignant primary tumor 3668 (32.9%)
Metastatic tumor 4639 (41.6%)
Recurrent primary tumor 1050 (9.4%)
Functional disease 485 (4.3%)
Intracranial lesions (5441)
Benign lesions 1176 (21.6%)
Acoustic neuroma 321 (5.9%)
Meningioma 360 (6.7%)
Benign, NOS 155 (2.9%)
Pituitary adenoma 88 (1.6%)
Primary malignant 226 (4.2%)
Astrocytoma 29 (0.6%)
Glioblastoma 76 (1.4%)
Glioma 8 (0.2%)
Meningioma, malignant 44 (0.8%)
Metastatic 2917 (53.6%)
Brain/cranial nerve/spinal cord 2867 (52.7%)
Meninges 4 (0.8%)
Recurrent 263 (4.8%)
Astrocytoma 19 (0.4%)
Glioblastoma 87 (1.6%)
Glioma 8 (0.2%)
Pituitary adenoma 16 (0.3%)
Functional disease 485 (9%)
Trigeminal neuralgia – typical 364 (6.7%)
Trigeminal neuralgia – atypical 99 (1.8%)
Trigeminal neuralgia- MS 13 (0.3%)
Extracranial lesions (6379)
Benign 42 (0.7%)
Head & neck 17 (0.3%)
Bones/joints 9 (0.2%)
Other nervous system 6 (0.1%)
Primary malignant 3442 (53.9%)
Lung/bronchus 1973 (30.9%)
Prostate 1165 (18.3%)
Pancreas 108 (1.7%)
Liver 50 (0.8%)
Metastatic 1722 (27%)
Lung/bronchus 601 (9.4%)
Bones/joints 338 (5.3%)
Table 3 Lesion characteristics and most common lesion
location and histology (Continued)
Liver 331 (5.2%)
Lymph node 150 (2.4%)
Recurrent 787 (12.4%)
Lung/bronchus 520 (8.2%)
Head and neck 98 (1.5%)
Gynecological 25 (0.4%)
Pancreas 21 (0.3%)
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reasons are listed in Table 1.
Forty-six percent of patients registered had no prior
treatment, 22% had previous chemotherapy, 19.1% had re-
ceived prior external beam radiation therapy and 17.7%
had undergone surgery (Table 2). Nearly fifteen percent of
patients were considered surgically inoperable at the time
of enrollment and 10% of cases were considered medically
inoperable. The primary baseline co-morbidities reported
for medically inoperable patients included pulmonary
(64.9%), cardiac (17.3%), vascular (3.5%) and neurological
(1.9%). Age was also reported as a contra-indication for
2% of medically inoperable patients.Tumor characteristics
At the time of this analysis, data were available on 11,820
lesions. A description of the lesion characteristics are
shown in Table 3. The most prevalent lesion type was
metastatic lesions (41.6%), followed by primary malignant
lesions (32.9%) benign lesions (10.9%), recurrent primary
lesions (9.4%), functional diseases (4.3%) and arterio-
venous malformations (0.8%). In total, there were 65 dif-
ferent SRS/SBRT anatomical treatment sites. The majority
of lesions were extracranial (54% extracranial vs. 46%
intracranial), but the predominant single treatment loca-
tion category was brain/cranial nerve/spinal cord which
represented 42.3% of all cases and 93% of intracranial le-
sions. The distribution of intracranial lesions by location is
shown in Figure 1. Three percent of all intracranial cases
were located in the meninges, 2.4% in the pituitary, 0.9%
in the cerebellum and 0.1% in the pineal gland. The distri-
bution of intracranial lesion by pathology/histology is
shown in Table 3. Metastases were the most prevalent
type of intracranial lesion (53.6%) with adenocarcinoma
and squamous cell carcinoma as the most common hist-
ology. The second most prevalent intracranial type of le-
sion was benign (21.6%) and the most common benign
histology was non-malignant meningioma (360 cases,
6.7% of intracranial lesions) and acoustic neuroma (321
cases, 5.9% of intracranial lesions). Recurrent tumors ac-
count for 4.8% of intracranial lesions with gliobastoma as
AB
Brain/cranial 
nerve/spinal 
cord, 93.5%
Cerebellum, 
0.9%
Meninges, 
3.2%
Pineal Gland, 
0.1% Pituitary, 2.4%
Bones/joints, 
5.99%
Breast, 0.24% GYN, 0.78%
Head & Neck, 
3.43%Kidney, 0.75%
Liver, 6.22%
Lung/bronchus, 
51.62%
Lymph nodes, 
2.62%
Other, 6.85%
Other GI, 0.36%
Pancreas, 2.34% Prostate, 18.56%
Skin, 0.24%
Figure 1 Location and percentage of intracranial lesions (A) and extracranial lesions (B) treated with SRS/SBRT.
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oma, astrocytoma and pituitary adenoma. Primary malig-
nant tumors were the least prevalent type of intracranial
lesion and account for 4.2% of intracranial cases. One half
of all primary malignant intracranial lesions fell into the
broad category glioma, with glioblastoma and astrocytoma
as the most prevalent types (Table 3). For the age group of
0–19 years, 18 of 21 lesions were located in brain/cranial
nerve/spinal cord and the most prevalent histology for this
age group was arterio-venous malformations, glioblastoma
and astrocytoma.
Trigeminal neuralgia was the most prevalent type of
functional disease (476 cases and 98% of functional dis-
eases). Typical and atypical trigeminal neuralgia account
for 75% and 20% of functional diseases, respectively(Table 3) and trigeminal neuralgia associated with mul-
tiple sclerosis was reported in 13 cases.
The distribution of extracranial lesions by site is shown
in Figure 1B. Lung/bronchus was the most prevalent extra-
cranial location (51.6% of extracranial cases), followed by
prostate (18.6%), liver (6.2%), bones/joints (6.0%), head and
neck (3.4%) lymph nodes (2.6%), and pancreas (2.3%).
Fifty-four percent of extracranial lesions were primary
malignant, 27% metastatic, 12.4% recurrent and 0.7% be-
nign (Table 3). There are 73 different histological classifica-
tions for primary lesions. The most common histology was
adenocarcinoma (46.9%) followed by non-small cell carcin-
oma (16.7%) and squamous cell carcinoma (15.0%). Other
histologies included hepatocellular carcinoma, small cell
carcinoma, renal cell carcinoma, and cholangiocarcinoma.
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was from lung/bronchus (19%), followed by large intestine
(15%), breast (11%), gynecological tumors (10%), head and
neck (9%), rectum (6%) and kidney (5%). Lung/bronchus
and head and neck lesions accounted for the most preva-
lent recurrent cases.
Treatment characteristics
SRS/SBRT was the primary treatment for 70% of lesions,
adjuvant treatment for 14.3%, and used as a boost treat-
ment for 9.7% of lesions (Table 4). The primary treat-
ment objective of SRS/SBRT treatment was palliative for
44.8% and curative for 39.8% of lesions. SRS/SBRT treat-
ment plan information was available for 8589 lesions.
The radiation dose delivered to the target varied signifi-
cantly across treatment locations, with the overall me-
dian dose of 30 Gy (range < 1 – 96.7 Gy) and the median
number of fractions delivered was 3.
For this analysis, we identified five common treatment
locations (brain, lung, liver, pancreas and prostate) to re-
port the treatment volume, prescription dose, number of
fractions and the maximum point dose to the organs at
risk (Table 5). For brain/cranial nerve/spine lesions, the
median volume was 3.3 cc (range < 1 – 804 cc), the me-
dian prescription dose was 24 Gy (range 2 – 96 Gy) andTable 4 SRS and SBRT treatment indication and
characteristics
Variable (N) N (%)
SRS/SBRT treatment indication (11072)
Primary treatment 7748 (70.0%)
Adjuvant treatment 1585 (14.3%)
Non-surgical boost 1077 (9.7%)
Post-operative treatment 231 (2.1%)
Post-operative for residual tumor 336 (3.0%)
Post-operative for cavity boost 83 (0.7%)
Pre-operative treatment 12 (0.1%)
SRS/SBRT treatment objective (11072)
Curative 4407 (39.8%)
Palliative 4958 (44.8%)
Other 564 (5.1%)
Not reported 1461 (12%)
Mean lesion volume, range (5890) 33.67 (0–5255 cc)
Median lesion size in x,y,z, mm 27.2, 24.6, 24.9
Median number of fiducials (range) 1 (1–9)
Median number of fractions (range) 3 (0–46)
Median prescription dose, range (8585) 30 (0 – 96.7 Gy)
Median maximum point dose, range (7953) 40.98 (0–100 Gy)
Most common collimator size, intracranial lesion 10 mm
Most common collimator size, extracranial lesion 20 mmmedian number of fractions was 1 (range 1 – 25). The me-
dian maximum dose was 5 Gy to the brainstem, 0.4 Gy to
the lens, 2 Gy to the optic chiasm and 1 Gy to the optic
nerve. For lung lesions, the median volume was 14 cc
(range 0.2 – 1751 cc), the median prescription dose was
54 Gy (range 11 – 80 Gy), and the median number of frac-
tions was 3(range 1 – 10). The median maximum dose was
11 Gy to the esophagus, 14 Gy to the heart, 12 Gy to the
trachea/bronchus, and 7 Gy to the spinal cord. For liver le-
sions, the median volume is 32 cc (range 1 – 877 cc), the
median prescription dose is 45 Gy (range 10 – 60 Gy) and
median number of fractions is 3 (range 1 – 5). The median
maximum dose was 60 Gy for uninvolved liver, 17 Gy to
the bowel, 6 Gy to the kidney, and 4 Gy to the spinal cord.
For lesions in the pancreas, the median volume is 34 cc
(range 2 – 172 cc), the median maximum dose was 29 Gy
(range 2 – 60 Gy) and the median number of fractions is 3
(range 1–5). The median maximum dose was 24 Gy to the
bowel, 5 Gy to the kidney, 22 Gy to the liver and 4 Gy to
the spinal cord. For the prostate, the median volume was
56 cc (range 6 – 296 cc), the median dose was 36.35 Gy
(6.5 – 80 Gy) delivered in 5 (range 1 – 38) fractions. The
median maximum dose was 41 Gy to the bladder, 14 Gy to
the femoral heads, 27 Gy to the penile bulb, 38 Gy to the
rectum and 43 Gy to the urethra.
Outcomes assessment
The goal of systematic collection of data in registries is to
track procedure and patient-related outcomes in order to
identify areas of success and opportunities for improve-
ment and utilization of resources. Outcomes for overall
survival and disease control are shown for one common
intracranial treatment site, brain metastases and one com-
mon extracranial treatment site, liver metastases. Patient
demographics and treatment characteristics for 799 pa-
tients with 952 brain metastases are shown in Table 6. The
number of lesions ranged from 1–7 and median tumor size
was 1.2 cm (range 0.1-34 cm). The majority of metastases
were from primary lung cancer (53.8%) and breast cancer
(15.1%), followed by melanoma (9%) and renal (5%) tu-
mors. Patients were treated with a median SRS dose of
22 Gy (range 2.4 – 45 Gy) delivered in a median of 1 frac-
tion (range 1 – 4). The median overall survival rate for this
cohort was 8 months. When stratified by baseline per-
formance score, patients with good performance status
with KPS > 70 had a median overall survival rate of
11 months compared to 4 months for patients with
KPS ≤ 70 (p < 0.0001 by log-rank test), as shown in
Figure 2. The 3-month, 6-month and 12-month local
control rates for patients with KPS ≤ 70 were 91%, 79%
and 61% respectively. For patients with KPS > 70, the
3-month, 6-month and 12-month local control rates were
95%, 85% and 74%, respectively. These results are compar-
able to rates reported from single institution studies and
Table 5 Doses for common treatment sites and organs at risk reported in RSSearch™
Treated organ Organs at risk Median volume
(range), cc
Median #
fractions (range)
Median dose
(range), Gy
Median max point
dose (range), Gy
Brain 3.3 (< 1 – 804) 1 (1 – 25) 24 (2 – 96) 30 (0 – 96)
Brain stem 5 (0 – 70)
Eye/lens 0.4 (0 – 70)
Optic chiasm 2 (0 – 51)
Optic nerve 1 (0 – 41)
Lung/bronchus 14 (0.2 – 1751) 3 (1 – 10) 54 (11 – 80) 71 (0 – 100)
Esophagus 11 (0 – 63)
Heart 14 (0 – 64)
Trachea/bronchus 12 (0 – 76)
Spinal cord 7 (< 1– 76)
Liver 32 (1– 877) 3 (1– 5) 45 (10 – 60) 58 (12 – 94)
Uninvolved liver 60 (18 – 75)
Bowel 17 (0 – 66)
Kidney 6 (0 – 64)
Spinal cord 4 (0 – 17)
Pancreas 34 (2 – 172) 3 (1 – 5) 29 (2 – 60) 38 (0 – 73)
Bowel 24 (0 – 56)
Kidney 5 (0 – 27)
Liver 22 (2 – 70)
Spinal cord 4 (0 – 13)
Prostate 56 (6 – 296) 5 (1– 38) 36.25 (6.5 – 80) 48 (9 – 86)
Bladder 41 (0.5 – 80)
Femoral heads 14 (0.5 – 111)
Penile bulb 27 (0.7 – 66)
Rectum 38 (6 – 78)
Urethra 43 (8 – 83)
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ated SRS for the treatment of brain metastases [37-40].
Patient demographic and treatment characteristics
for 174 patients with 204 liver metastases are shown
in Table 7. The median follow-up was 11 months
(range 1–59 months). The median lesion size was
2.7 cm (range 0.12 – 12.3 cm) and median lesion volume
was 27.3 cc (range 1 – 606 cc). Fifty percent of the
patients had liver metastases from colorectal cancer,
10.8% from lung, and 8.8% from breast cancer. Patients were
treated with SBRT doses of 10 – 61 Gy (median 45 Gy)
delivered in 1–5 fractions (median 3 fractions). Kaplan-Meier
survival curves are shown in Figure 3. Median overall
survival was 22 months and overall survival rates at
6, 12 and 18 months were 91%, 69% and 60%, respectively.
Local progression-free survival at 6, 12 and 18 months
was 94%, 76% and 70%, respectively. Distant disease
progression-free survival at 6, 12 and 18 months was 77%,
53% and 37%, respectively. The median time to distantprogression was 14 months. These results demonstrated
that patient-related outcomes can be performed from
RSSearch™ Registry data. Future outcome measures could
be evaluated for all treatment sites including surrogate
outcome measures like biochemical progression free
survival (prostate cancer) and neurological function
preservation (acoustic neuroma).
Discussion
The Agency for Healthcare Research and Quality (AHRQ)
defines a patient registry as “an organized system that uses
observational study methods to collect uniform data
(clinical and other) to evaluate specified outcomes for a
population defined by a particular disease, condition, or
exposure, and that serves one or more predetermined sci-
entific, clinical, or policy purposes” [32]. Registry use oc-
curs on a variety of levels, ranging from clinic logs to rare
disease entities to international disease databases. Data
collected often include demographic information such as
Table 6 Patient and treatment details of SRS for brain
metastases
Variable (N) N (%)
Gender (799 patients)
Male 354 (44%)
Female 445 (56%)
Median age (range), years 63 (23 – 94)
Median Karnofsky score (range) 80 (30–100)
Previous treatment
Surgery 167 (18%)
External beam radiation 361 (37%)
Radiosurgery 111 (12%)
Chemotherapy 276 (29%)
Other 12 (1%)
None 338 (36%)
Primary tumor site (952 lesions)
Lung 512 (53.8%)
Breast 144 (15.1%)
Melanoma 88 (9.2%)
Renal 48 (5.0%)
Colorectal 40 (4.2%)
Head and neck 30 (3.2%)
Gynecological 15 (2.0%)
Other 75 (7.8%)
Median lesion volume, cc 2.1 (0.1 – 113)
Median lesion size, cm 1.2 (0.1 – 34)
Median number of lesions (range) 1 (1 – 7)
Median number of fractions 1 (1 – 5)
Median dose (range), Gy 22 (2..4 – 45)
Prescription dose range (n = 924)
≤ 18 Gy 223 (24%)
19-20 Gy 174 (19%)
21-22 Gy 187 (20%)
22.5 – 24 Gy 189 (20%)
25 – 30 Gy 132 (14%)
> 30 Gy 18 (2%)
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http://www.ro-journal.com/content/8/1/275sex and age, medical history, diagnostic information,
procedure and device specifics, and clinical outcomes.
The uniform collection of these data creates a better
understanding of practice characteristics, treatments,
diseases, and outcomes. In their most practical use,
registries can help identify which patients have a
certain condition or disease, or follow patients receiv-
ing certain devices or treatments. The RSSearch™
Registry fulfils this ideal for patients treated with SRS
and SBRT.Multi-institutional, observational patient registries can
be powerful tools to describe disease presentation, pat-
terns of care, treatment effectiveness, safety and quality
of care in a real-world setting [33-35]. The Society of
Thoracic Surgery Cardiac Surgery National Database,
which began in 1989 and includes over five million patient
records, has been used to report treatment patterns,
support quality improvement initiatives, develop clinical
treatment guidelines, support comparative effectiveness
studies, government collaborations, regulatory compliance
and reimbursement strategies for cardiac and thoracic pa-
tients [34,41-43]. The American Society of Breast Sur-
geons (ASBS) MammoSite™ Registry began in 2002, as a
manufacturer-sponsored registry developed to provide in-
formation on the optimal use of the device in clinical
practice [35]. The ASBS assumed responsibility of the
database in 2003, and have reported outcomes from the
registry demonstrating efficacy, safety and improved qual-
ity of life for early-stage breast cancer patients treated with
breast-conserving therapy.[44,45] The ASBS have been
consistently following-up and reporting on the use of
MammoSite™ as the registry matures and continues to re-
port on clinical outcomes of partial breast irradiation even
before formal prospective data from randomized clinical
trials becomes available [46,47]. Clinical outcome data
from registries have also been used to determine coverage
(payment) policies. The Centers for Medicare & Medic-
aid Services expanded its coverage for PET scans in
diagnosis of certain cancers because of information ob-
tained through the National Oncologic PET Registry
[33]. These reports demonstrate the potential impact
registries can provide to the medical community, pa-
tient care and treatment practices.
In this report, we demonstrate that patterns of care for
SRS/SBRT can be collected in a multi-institutional data-
base and patterns of care research can be performed.
We describe the initial patient demographics, lesion char-
acteristics and SRS/SBRT treatment for 11,457 patients en-
rolled in the RSSearch™ Registry. To our knowledge, this is
the largest aggregate report of SRS/SBRT-treated patients
in a published registry. As one might expect, lesions in the
brain/cranial nerve/spinal cord were the single most preva-
lent treatment location in RSSearch™, which correlates with
the long history of SRS experience for intracranial lesions.
The median SRS dose and fractionation schedule for brain
lesions reported in RSSearch™ was 24 Gy delivered in
1 fraction. A single fraction of 24 Gy is the recommended
dose used in to treat 1–3 metastatic brain lesions up to
2 cm as described in RTOG 9508 and RTOG 9005 [37,48]
and SRS delivered as a single fraction (15–24 Gy) to indi-
vidual intracranial lesions has been established as a safe
alternative to surgical resection [39,49]. In a subset analysis,
we reported a median overall survival rate of 11 months for
patients with brain metastases with a good performance
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http://www.ro-journal.com/content/8/1/275score (KPS > 70) compared to 4 months for patients with
KPS ≤ 70. Outcomes for patients with brain metastases are
generally poor with a median survival following whole brain
radiation therapy (WBRT) alone of 3–6 months [37,39,50].
The addition of SRS following WBRT and SRS alone
have improved overall survival and local control rates.
Rades et al. showed a 13 month overall survival rate
for SRS alone compared to 7 months for WBRT [40].
One-year local control rate for SRS alone was 64% com-
pared to 26% for WBRT. Li et al. compared WBRT vs. SRS
vs. WBRT plus SRS and showed a median survival rate of
5.7 months, 9.3 months and 10.6 months, respectively [51].
KPS has been shown to be a predictor of survival for
patients with brain metastases [52]. Using recursive parti-
tioning analysis of three RTOG trials, the best survival
(median 7.1 months) was observed in patients < 65 years,
KPS of at least 70 and a controlled primary tumor with
brain as the only site of metastases. The worst survival
(median 2.3 months) was seen in patients with KPS < 70.
In our study, overall survival was significantly greater inpatients with KPS > 70 compared to KPS ≤ 70, correlating
with previous reports.
When using high doses of radiation with SRS/SBRT,
there is critical importance to minimize the volume of
normal tissues receiving high dose per fraction in order
to protect normal tissues from adverse radiation effects.
The American Association of Physicists in Medicine
(AAPM) task group and others have defined normal
dose limits for organs at risk for SBRT from published
literature and randomized clinical trials [53-55]. We cal-
culated the median maximum point dose for organs at
risk from the treatment plans in RSSearch™ in order to
compare to reported treatment guidelines. For the brain-
stem, eye/lens, optic chiasm and optic nerve, the median
max point dose in RSSearch™ was 5, 0.4, 2 and 1 Gy, re-
spectively, which is below the recommended max point
dose ranges of 15–31 Gy for the brainstem, 2–3 Gy for
the eye/lens, 10–15 Gy for optic chiasm and 8–15 Gy
for optic nerve when delivered in 1 fraction [53,54]. Fur-
thermore, with automated data entry from treatment
Table 7 Patient and treatment details of SBRT for liver
metastasis
Variable (N) N (%)
Gender (174 patients)
Male 95 (54%)
Female 79 (45%)
Median age (range), years 69 (41 – 91)
Median Karnofsky score (range) 90 (50–100)
Previous treatment
Surgery 22 (12%)
External beam radiation 7 (4.0%)
Radiosurgery 8 (4.6%)
Chemo embolization 1 (0.6%)
Radiofrequency ablation 5 (2.9%)
Chemotherapy 103 (59.2%)
None 54 (31.0%)
Primary tumor site (204 lesions)
Colorectal 103 (50.5%)
Lung 22 (10.8%)
Breast 18 (8.8%)
Pancreas 9 (4.4%)
Gynecological 9 (4.4%)
Gastric 9 (4.4%)
Head and neck 7 (3.4%)
Malignant melanoma 4 (2.0%)
Anal 3 (1.5%)
Kidney 2 (1%)
Intrahepatic bile duct 2 (1%)
Other 14 (6.9%)
Median lesion volume, cc 27.3 (1–606)
Median lesion size, cm 2.7 (0.12 – 12.3)
Median number of lesions (range) 1(1–4)
Median number of fractions 3 (1–5)
Median dose (range), Gy 45 (10 – 61)
Prescription dose range
10 – 30 Gy 35 (16.7%)
33 – 39 Gy 45 (21.6%)
40 – 45 Gy 42 (20.6%)
46.5 – 48 Gy 18 (8.8%)
51 – 54 Gy 38 (18.6%)
57 – 60 Gy 28 (13.7%)
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http://www.ro-journal.com/content/8/1/275platforms, more stringent dose-volume histogram ana-
lysis of all targets and organs at risk can be performed.
These results indicate that most participating centers
treating intracranial lesions adhere to recommended
guidelines for tolerance limits for normal organs.In this analysis, we also examine patient demographics,
treatment practices and outcomes of liver metastases, a
common extracranial treatment location. Currently, there
is no consensus for the treatment of primary liver tumors
and liver metastases with radiation. In 2012, the Liver
Cancer Workgroup of the Third International Consensus
on Metastases Workshop at the 2010 American Society
for Radiation Oncology meeting published an inter-
national survey on the status of radiation therapy of liver
metastases [56]. The survey indicated there was a 54% in-
crease in the average number of liver referrals over the
past 5 years and the majority of referrals were for SBRT.
No uniform SBRT treatment dose was identified and there
was a wide variation of treatment regimens which were
dependent on whether the treatment objective was cura-
tive or palliation. The group concluded there is a need for
prospective studies and registries for comparison of
treatment regimens and identification of parameters to
optimize patient selection. Interestingly, liver is the third
most common extracranial SBRT treatment location in
RSSearch™ and SBRT is being used as both a palliative and
curative treatment option for liver lesions. The SBRT dose
ranged from 10 – 60 Gy delivered over 1–5 fractions, with
the median SBRT dose of 45 Gy delivered in 3 fractions.
The median OS was 22 months and OS 6, 12 and
18 months were 91%, 69% and 60%, respectively. LPFS at
6, 12 and 18 months was 94%, 76% and 70%, respectively.
In our analysis of this patient group (n = 174) with a wide
variety of underlying primary tumors, different systemic
and local treatments, lesion sizes and dose/fractionation
schedules the OS and local control rates were within the
range of published reports[57,58]. Future studies are
planned to examine prognostic factors and the effect of
dose/fractionation schedules on OS and local control from
the RSSearch™ dataset.
The most prevalent extracranial treatment site in
RSSearch™ was lung/bronchus. This correlates with the
AHRQ 2011 report which described the current state of
SBRT as an emerging technology for the treatment of
solid malignant tumors and identified lung/thorax as the
most common site treated with SBRT [59]. SBRT is now
considered a standard treatment option for medically in-
operable patients through prospective, multi-institutional
trials [60,61]. There is a wide variety of SBRT dose and
fractionation schedules reported for lung lesions which
range from single fractions of 19–34 Gy [62-64] to hypo-
fractionated schedules of 50–66 Gy delivered in 3–5 frac-
tions [13,65-67]. In RSSearch™, the median SBRT dose to
lung lesions was 54 Gy delivered in 3 fractions, which is in
line with other published reports. We also reported the
median maximum point dose to the esophagus, heart, tra-
chea/bronchus and spinal cord reported in RSSearch™ and
demonstrated that the median values all fell below the rec-
ommendations for normal dose limits described by the
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http://www.ro-journal.com/content/8/1/275AAPM Task Group and RTOG 0618 [53]. It is reassuring
to note that these tolerance doses to organs at risk were
more that met without compromising on outcomes. The
outcomes reported in Figures 2 and 3 from this study are
comparable for this population to other studies. Moreover,
these results may be more generalizable than single in-
stitution or prospective controlled studies. The results
also suggest that the majority of centers participating in
RSSearch™ are following the standardized treatment
guidelines, published reports and protocols for SBRT for
the treatment of lung cancer. Future studies are planned
to obtain the entire treatment plan to correlate clinical
outcomes with DVHs as well as analyze and report on
the treatment management practices and clinical out-
comes of lung cancer patients in RSSearch™.
The second most common extracranial site in RSSearch™
was the prostate. SBRT treatment of early stage organ-
confined prostate cancer has become increasingly popular,
as initial studies have demonstrated excellent biochemical
control rates with very minimal toxicity [16,19,68]. In April
2013, ASTRO published their SBRT Model Policy statingthat SBRT was an appropriate treatment option for select
patients with low to intermediate risk prostate cancer and
should be included in coverage (payment) policies [69].
Several studies have shown 5-year biochemical disease-free
survival rates of 90-97% when using doses of 35 – 36.25 Gy
when delivered in 5 fractions for low and intermediate risk
disease. The median dose in RSSearch™ was 36.25 Gy in 5
fractions. The median max point dose to the urethra, rec-
tum, penile bulb and femoral heads was 43, 38, 27 and
14 Gy, respectively, and fell below the published recom-
mended normal dose tolerances (max dose of 35 – 47 Gy
for urethra, 21 – 38 Gy for rectum, 50 Gy for penile
bulb, and 30 Gy for femoral heads) [53,54]. The median
max point dose for the bladder was 41 Gy and slightly
higher than published recommendations ranging from
24 – 25 Gy. Future studies from RSSearch™ will be
conducted to compare dose volume histograms of target
and organs at risk to correlate clinical outcomes and
toxicities.
SBRT has been evaluated for the treatment of locally ad-
vanced pancreatic with mixed results [20-23]. Variations in
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http://www.ro-journal.com/content/8/1/275SBRT dose and fractionation schedules in conjunction with
different chemotherapeutic agents and schedules have
made the interpretation of clinical results and optimization
of patient selection challenging. SBRT doses have ranged
from 15 – 25 Gy in a single fraction to 24 – 45 Gy
in 3 fractions with concurrent gemcitibine [20,21,23].
The University of Texas Southwest Medical Center,
Dallas, TX have initiated a Phase I trial where patients
with surgically resectable pancreatic cancer receive 30 Gy
SBRT in 1 fraction to the surgically inaccessible at-risk
margin prior to surgery, in effort to reduce local failure
following surgery [70]. These studies indicate that SBRT
can be an effective treatment option for pancreatic cancer,
but its optimal use remains to be determined. The median
SBRT dose for pancreatic lesions reported RSSearch™ was
29 Gy delivered in 3 fractions. Future studies will be con-
ducted to investigate variations in treatment management
practices and clinical outcomes for pancreatic cancer
patients enrolled in RSSearch™.
The RSSearch™ registry was feasible as it was nurtured
by a SRS/SBRT specialty society. Medical specialty soci-
eties are organizations that represent networks of physi-
cians. These organizations often exist to provide services
to their members in the areas of advocacy, education,
and practice management. Based on their close inter-
action with their members and their national and inter-
national reach, medical specialty societies are uniquely
positioned to collect and manage data related to the type
of care their members provide. Medical specialty soci-
eties are able to connect with the members directly at
meetings and symposia, and by using direct-to-member
correspondences. The Radiosurgery Society, an independ-
ent non-profit organization of professionals dedicated to
SRS/SBRT will foster and champion the maintenance and
future success of the registry.
Conclusion
This is the first report to describe a multi-center observa-
tional patient registry dedicated to SRS/SBRT treatments
under the auspices of a medical specialty society. The
RSSearch™ Registry hosts a comprehensive cache of infor-
mation regarding SRS and SBRT treatments. It provides
valuable information on practice patterns, procedure and
patient related outcomes and serves as a valuable tool for
surveillance and audit of emerging treatment modalities
like SRS and SBRT. This repository would serve in com-
parative effectiveness research and to generate hypothesis
for future research. The information in the registry may
complement randomized clinical trials in a real-life clinical
setting providing generalizable data. They may be useful to
identify new risk factors and/or tumor characteristics that
may benefit from SRS/SBRT. Future studies focusing on
health-related outcomes from patients in RSSearch™ have
been initiated and will be reported in subsequent analysis.Competing interests
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